See more : General de Alquiler de Maquinaria, S.A. (GAM.MC) Income Statement Analysis – Financial Results
Complete financial analysis of Zydus Lifesciences Limited (ZYDUSLIFE.NS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Zydus Lifesciences Limited, a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- First Tractor Company Limited (FIRRF) Income Statement Analysis – Financial Results
- Babcock & Wilcox Enterprises, I (BWSN) Income Statement Analysis – Financial Results
- TB Group Inc. (6775.T) Income Statement Analysis – Financial Results
- Tian Ruixiang Holdings Ltd (TIRX) Income Statement Analysis – Financial Results
- FTAC Zeus Acquisition Corp. (ZINGU) Income Statement Analysis – Financial Results
Zydus Lifesciences Limited (ZYDUSLIFE.NS)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.zyduslife.com
About Zydus Lifesciences Limited
Zydus Lifesciences Limited engages in the research, development, production, marketing, distribution, and sale of pharmaceutical products in India, the United States, Europe, Latin America, the Asia Pacific, and Africa. The company operates in Pharmaceuticals and Consumer Products segments. It offers finished dosage human formulations comprising generics, branded generics, and specialty formulations, including biosimilars and vaccines; active pharmaceutical ingredients; consumer wellness products; and products in the therapeutic areas of pain management, neurology, dermatology, liver diseases, and other areas. The company also provides consumer wellness products, such as Complan; EverYuth, a range of skincare products; Nycil; Glucon-D glucose powder; Nutralite; Nutralite Doodhshakti, a portfolio of dairy products; and various other products. In addition, the company offers a pipeline of biological products in the areas of oncology, autoimmune disease, nephrology, ophthalmology, inflammation, rheumatology, hepatology, infectious disease, etc. Further, it engages in the investment, animal health and veterinary, pharmacy retail, and manpower supply and administration activities. The company was formerly known as Cadila Healthcare Limited and changed its name to Zydus Lifesciences Limited in February 2022. Zydus Lifesciences Limited was founded in 1952 and is based in Ahmedabad, India.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 195.47B | 168.78B | 148.28B | 148.22B | 138.12B | 127.48B | 115.99B | 94.30B | 98.38B | 86.51B | 72.24B | 63.58B | 50.90B | 44.65B | 36.87B | 28.62B | 22.66B | 17.86B | 14.45B | 12.43B | 11.96B |
| Cost of Revenue | 106.23B | 63.10B | 58.19B | 54.80B | 51.49B | 49.50B | 43.43B | 36.36B | 34.60B | 33.10B | 28.21B | 24.08B | 20.56B | 14.75B | 11.78B | 9.57B | 7.90B | 6.37B | 5.69B | 4.84B | 5.01B |
| Gross Profit | 89.25B | 105.68B | 90.09B | 93.42B | 86.63B | 77.99B | 72.56B | 57.93B | 63.78B | 53.42B | 44.03B | 39.49B | 30.35B | 29.89B | 25.08B | 19.06B | 14.76B | 11.48B | 8.77B | 7.59B | 6.96B |
| Gross Profit Ratio | 45.66% | 62.61% | 60.76% | 63.03% | 62.72% | 61.17% | 62.56% | 61.44% | 64.83% | 61.74% | 60.95% | 62.12% | 59.62% | 66.95% | 68.04% | 66.58% | 65.12% | 64.31% | 60.64% | 61.06% | 58.14% |
| Research & Development | 13.13B | 1.36B | 1.15B | 1.18B | 897.00M | 1.08B | 1.69B | 1.44B | 1.39B | 1.09B | 574.00M | 823.00M | 0.00 | 2.50B | 1.66B | 1.56B | 1.34B | 1.34B | 797.00M | 736.00M | 615.00M |
| General & Administrative | 5.18B | 5.83B | 4.28B | 4.72B | 5.44B | 3.40B | 2.75B | 2.46B | 2.32B | 1.77B | 1.79B | 1.40B | 0.00 | 18.78B | 15.34B | 1.53B | 1.40B | 926.00M | 495.00M | 684.00M | 703.00M |
| Selling & Marketing | 16.58B | 15.57B | 13.73B | 13.88B | 13.34B | 10.35B | 10.15B | 8.30B | 10.20B | 9.60B | 9.02B | 7.89B | 0.00 | 0.00 | 0.00 | 5.54B | 4.09B | 3.01B | 2.25B | 1.81B | 1.45B |
| SG&A | 29.64B | 21.40B | 18.01B | 18.60B | 18.78B | 13.75B | 12.89B | 10.75B | 12.52B | 11.37B | 10.82B | 9.29B | 0.00 | 18.78B | 15.34B | 7.07B | 5.49B | 3.94B | 2.75B | 2.50B | 2.15B |
| Other Expenses | -455.00M | 1.87B | 31.00M | 51.00M | 84.00M | 81.00M | 46.00M | 80.00M | 131.00M | 92.00M | 28.00M | 24.00M | 24.32B | -517.00M | -46.00M | 5.28B | 4.29B | 3.24B | 2.12B | 2.48B | 2.34B |
| Operating Expenses | 83.11B | 77.15B | 65.32B | 67.15B | 66.06B | 54.76B | 49.56B | 42.57B | 42.93B | 38.53B | 33.92B | 29.98B | 24.32B | 20.77B | 18.18B | 13.91B | 11.12B | 8.52B | 5.67B | 5.71B | 5.10B |
| Cost & Expenses | 147.04B | 140.25B | 123.51B | 121.95B | 117.55B | 104.26B | 92.99B | 78.94B | 77.53B | 71.62B | 62.14B | 54.06B | 44.87B | 35.52B | 29.96B | 23.48B | 19.02B | 14.89B | 11.36B | 10.55B | 10.11B |
| Interest Income | 1.27B | 757.00M | 688.00M | 503.00M | 325.00M | 530.00M | 494.00M | 573.00M | 601.00M | 387.00M | 343.00M | 267.00M | 144.00M | -112.00M | -119.00M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 492.00M | 1.30B | 1.14B | 1.60B | 3.24B | 1.91B | 1.05B | 568.00M | 410.00M | 555.00M | 1.10B | 1.17B | 1.05B | 587.00M | 702.00M | 1.21B | 335.00M | 223.00M | 251.00M | 245.00M | 210.00M |
| Depreciation & Amortization | 7.64B | 7.23B | 7.13B | 6.70B | 6.97B | 5.99B | 5.39B | 3.73B | 3.02B | 2.87B | 2.01B | 1.85B | 1.58B | 1.27B | 1.34B | 1.12B | 969.00M | 823.00M | 779.00M | 716.00M | 712.00M |
| EBITDA | 56.22B | 34.42B | 36.71B | 32.33B | 25.25B | 31.77B | 29.80B | 20.51B | 24.44B | 18.01B | 12.34B | 11.55B | 11.22B | 10.39B | 8.25B | 6.26B | 4.66B | 3.79B | 2.72B | 2.33B | 2.56B |
| EBITDA Ratio | 28.76% | 23.98% | 23.12% | 22.94% | 20.15% | 23.89% | 25.23% | 21.09% | 25.02% | 20.84% | 17.73% | 17.62% | 14.95% | 23.28% | 22.36% | 21.88% | 20.33% | 21.20% | 20.15% | 19.77% | 21.42% |
| Operating Income | 45.40B | 28.53B | 24.74B | 27.36B | 21.02B | 23.93B | 23.00B | 15.36B | 20.85B | 14.89B | 10.11B | 9.51B | 6.03B | 9.12B | 6.91B | 5.14B | 3.64B | 2.96B | 3.10B | 1.88B | 1.85B |
| Operating Income Ratio | 23.22% | 16.90% | 16.69% | 18.46% | 15.22% | 18.77% | 19.83% | 16.29% | 21.19% | 17.21% | 13.99% | 14.96% | 11.84% | 20.44% | 18.73% | 17.97% | 16.05% | 16.59% | 21.43% | 15.11% | 15.47% |
| Total Other Income/Expenses | 2.69B | -2.63B | 3.64B | -2.89B | -5.61B | 504.00M | 306.00M | 1.21B | 570.00M | -434.00M | -683.00M | -1.43B | -1.57B | -699.00M | -867.00M | -1.45B | -482.00M | -223.00M | -366.00M | -373.00M | -336.00M |
| Income Before Tax | 48.09B | 25.90B | 28.38B | 22.85B | 14.95B | 23.82B | 23.31B | 16.12B | 21.24B | 14.46B | 9.42B | 8.09B | 7.94B | 8.43B | 6.04B | 3.70B | 3.23B | 2.74B | 1.77B | 1.37B | 1.52B |
| Income Before Tax Ratio | 24.60% | 15.34% | 19.14% | 15.42% | 10.83% | 18.69% | 20.09% | 17.09% | 21.59% | 16.71% | 13.04% | 12.72% | 15.60% | 18.87% | 16.38% | 12.92% | 14.27% | 15.34% | 12.23% | 11.03% | 12.67% |
| Income Tax Expense | 9.78B | 5.88B | 5.12B | 1.47B | 3.20B | 5.30B | 5.64B | 1.29B | 5.71B | 2.59B | 1.06B | 1.19B | 1.13B | 1.06B | 741.00M | 666.00M | 613.00M | 324.00M | 243.00M | 192.00M | 213.00M |
| Net Income | 38.60B | 19.60B | 44.87B | 21.34B | 11.77B | 18.49B | 17.76B | 14.88B | 15.23B | 11.49B | 8.04B | 6.54B | 6.53B | 7.11B | 5.05B | 3.03B | 2.58B | 2.34B | 1.52B | 1.22B | 1.33B |
| Net Income Ratio | 19.74% | 11.61% | 30.26% | 14.40% | 8.52% | 14.50% | 15.31% | 15.78% | 15.48% | 13.28% | 11.12% | 10.28% | 12.82% | 15.92% | 13.70% | 10.59% | 11.37% | 13.09% | 10.54% | 9.77% | 11.13% |
| EPS | 38.14 | 19.30 | 17.65 | 20.84 | 11.49 | 18.06 | 17.35 | 14.53 | 19.19 | 11.24 | 7.85 | 6.38 | 6.37 | 6.95 | 3.29 | 3.20 | 2.73 | 2.48 | 161.73 | 2.55 | 2.83 |
| EPS Diluted | 38.14 | 19.30 | 17.65 | 20.84 | 11.49 | 18.06 | 17.35 | 14.53 | 19.19 | 11.24 | 7.85 | 6.38 | 6.37 | 6.95 | 3.29 | 3.20 | 2.73 | 2.48 | 161.73 | 2.55 | 2.83 |
| Weighted Avg Shares Out | 1.01B | 1.02B | 1.02B | 1.02B | 1.02B | 1.02B | 1.02B | 1.02B | 1.02B | 1.02B | 1.02B | 1.02B | 1.02B | 1.02B | 1.02B | 1.02B | 942.10M | 942.10M | 942.10M | 471.05M | 471.05M |
| Weighted Avg Shares Out (Dil) | 1.01B | 1.02B | 1.02B | 1.02B | 1.02B | 1.02B | 1.02B | 1.02B | 1.02B | 1.02B | 1.02B | 1.02B | 1.02B | 1.02B | 1.02B | 1.02B | 942.10M | 942.10M | 942.10M | 471.05M | 471.05M |
Source: https://incomestatements.info
Category: Stock Reports